Latest Drug development biotechnology articles and news on biotech industry leaders, emerging biotech companies in Spain

INCLIVA inicia un ensayo clínico contra la mielofibrosis

by INCLIVA

9 years ago
mielofibrosis

El objetivo del estudio es evaluar la respuesta, en términos de reducción de la esplenomegalia (agrandamiento del bazo) y de los síntomas, así como la toxicidad de este medicamento, a dos dosis di...

Comienza un ensayo clínico para combatir los tumores escamosos de pulmón bloqueando dos efectores del gen RAS

by Clínica Universidad de Navarra

9 years ago
tumores escamosos de pulmón, cáncer de pulmón, oncogén RAS

Se clausura el II Congreso “International Frontiers in Oncology”, organizado por la Clínica Universidad de Navarra, el CIMA y la Universidad de Stanford, en el que han participado 200 investigado...

Ability Pharmaceuticals announces regulatory milestones for ABTL0812 in pediatric cancer neuroblastoma

by Ability Pharma

9 years ago
pediatric cancer, neuroblastoma, orphan-drug, ABTL0812, Food and Drug Administration

Ability Pharmaceuticals today announced that it has received from the U.S. Food and Drug Administration (FDA), orphan-drug designation (ODD) for ABTL0812, its PI3K/Akt/mTOR pathway inhibitor, for the ...

Sanofi and AB-Biotics create formula to ease colic in babies

by Biocat

9 years ago
AB-Kolicare®, Sanofi, AB-Biotics, Baby colic

The probiotic formula, developed by the Catalan biotechnology company, will be the first that pharmaceutical corporation Sanofi will market in Spain

Sintetizan nuevos productos farmacéuticos a partir de esteroides

by DiCYT - Agencia Iberoamericana para la Difusión de la Ciencia y la Tecnología

9 years ago
esteroides

La importancia de desarrollar nuevas rutas sintéticas radica además en que las modificaciones en la estructura de los esteroides orgánicos y la introducción de nuevas sustancias pueden dar lugar a...

Artax Biopharma Raises $10M Series B to fund Phase Ib-IIa clinical trials for AX-024, a novel oral treatment for autoimmune diseases and to further develop its pipeline of preclinical candidates

by Parc Científic de Barcelona

9 years ago
Advent Life Sciences, Artax Biopharma, AX-024 compound

Artax has validated the target and mechanism of action, and demonstrated preclinical proof of concept of AX-024 in various preclinical autoimmune disease (MS, Psoriasis, IBD, Type I diabetes) and GVHD...

UB researchers develop a new family of bioinspired antibiotic compounds

by Xarxa de Referència en Biotecnologia (XRB)

9 years ago
antibacterial compound, peptides, Gram-negative bacteria, Gram-positive bacteria, antibiotics

The study has proved that these compounds are highly active against clinically relevant Gram-negative and Gram-positive bacteria. In vitro and in vivo tests have showed compounds’ low toxicity. Bact...

Ability Pharmaceuticals announces positive Phase 1/1b study results of ABTL0812 in cancer patients with advanced solid tumors

by Ability Pharma

9 years ago
cancer, ABTL0812, drug development, advanced solid tumors

Study confirms that ABTL0812 is extremely well tolerated and shows promising signs of clinical antitumor activity. The results will be presented at AACR-NCI-EORTC International Conference on Molecular...

Científicos de la Universidad de Granada patentan un nuevo fármaco eficaz frente al cáncer de mama, colon y melanoma

by Universidad de Granada

9 years ago
cáncer de mama, cáncer de colon, melanoma, fármaco, Células Madre Cancerígenas

El nuevo compuesto permitió reducir en más de un 50 por ciento la actividad tumoral tras 41 días de tratamiento, en ratones a los que previamente se les había inducido un tumor. Entre sus ventajas...

Nanomateriales porosos para sustituir el ácido sulfúrico como catalizador en procesos de Química Fina

by Universidad de Córdoba

9 years ago
Nanomateriales porosos, ácido sulfúrico, química fina

Estos nanomateriales presentan de forma experimental dos ventajas respecto a los catalizadores convencionales: son más reutilizables y más limpios que el ácido sulfúrico, y presentan mejor comport...

Palobiofarma signs licensing agreement to develop novel adenosine-based immuno-oncology treatments

by Palobiofarma

9 years ago
lung cancer, licensing agreement, drug development, PBF-509, Palobiofarma, Novartis

Under the terms of the agreement Novartis will acquire exclusive global rights to develop, manufacture and commercialize Palobiofarma´s adenosine A2Areceptor antagonist PBF-509, currently entering Ph...

Public-private research: the University of Barcelona (UB) and the Hospital Clínic collaborate with Boehringer Ingelheim

by Fundació Bosch i Gimpera

9 years ago
Boehringer Ingelheim, lung cancer, University of Barcelona, Hospital Clínic of Barcelona, nintedanib

This study goes a step further and investigates nintedanib* effectiveness in squamous cell carcinoma, so it will use new preclinical cell crops models, unique in Spain, that allow interaction between ...